← Leaderboards
Robert Koenekoop
Lsu Health Sciences Center
$860,199
Attributed
$1,720,397
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $357.6K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,720,397 · 1
By mechanism
R01$1,720,397 · 1
Top collaborators
- Jennifer Jean Lentz5 shared
Most similar at Lsu Health Sciences Center
Same institution · by research overlap
- Jennifer Jean Lentz$1,506,418
- Katelyn N Robillard$148,508
- Wu Zhou$7,597,386
- Jason Dongjoon Kim$48,755
Others in their field
Other Emerging Leaders on “Drug Industry”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$115,774,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,260,629
- Klaus Romero · Critical Path Institute$88,280,928
- John Damon Chodera · Sloan-Kettering Inst Can Research$41,165,297
Research focus
Drug IndustryEffective TherapyAntisense OligonucleotidesDrug CandidateAntisense Oligonucleotide TherapyAffectAreaCanadaAuditoryChemistryCiliaClinicBehaviorClinical ResearchBlindnessClinical TrialsCochleaCohortCommunicationCellsDeafnessDefectDoseEmployment
Grant awards (5)
Antisense therapy for the treatment of visual loss in Usher syndrome$345,880
R01 · FY2023 · EY
Antisense therapy for the treatment of visual loss in Usher syndrome$335,504
R01 · FY2022 · EY
Antisense therapy for the treatment of visual loss in Usher syndrome$335,503
R01 · FY2021 · EY
Antisense therapy for the treatment of visual loss in Usher syndrome$345,880
R01 · FY2020 · EY
Antisense therapy for the treatment of visual loss in Usher syndrome$357,630
R01 · FY2019 · EY